EACTS 2014, page-42

Great pickup Terry, I found a statement made by Lee Rodne back in Oct 2012.

"Rodne said Allied expected to release data on heart valve reconstructions in the next quarter, an application that is outside of congenital heart disease. “It’s not just for people born with congenital heart disease, but also in the adult heart valve industry, which alone is a billion dollar industry. “Surgeons today don’t have the materials to give them the confidence to repair a heart valve, so that’s why most people get a replacement heart valve. “So we’re coming out with data in the next quarter on using the CardioCel tissue product to repair and reconstruct these valves to give surgeons the ability to repair them versus replace them. “From a clinical perspective it’s much better to repair something for the longevity than to replace.”

later they published this announcement

- http://www.asx.com.au/asxpdf/20121128/pdf/42bj9v31ypmlmt.pdf

Also remember this -



"To date, CardioCel® has been used in a range of cardiovascular repair and reconstruction procedures in both adults and paediatrics, including hole-in-the-heart repairs and heart valve reconstructions. Recently, in the US, CardioCel® has been used in less-invasive robotic surgery to repair defective heart valves which is a major step forward for the use of CardioCel® in cardiovascular surgery."


CardioCel continues to tick all the boxes.